Papular xanthoma is a rare cutaneous non-Langerhans cell histiocytosis in which papules are composed predominantly of xanthomatized macrophages. The classic clinicopathologic series frames it as a normolipemic skin-limited disorder, although pediatric exceptions with abnormal lipid profiles have been reported.
Ask a research question about Papular xanthoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Papular xanthoma:
name: Papular xanthoma
creation_date: "2026-05-07T23:30:22Z"
updated_date: "2026-05-08T00:01:00Z"
description: >
Papular xanthoma is a rare cutaneous non-Langerhans cell histiocytosis in
which papules are composed predominantly of xanthomatized macrophages. The
classic clinicopathologic series frames it as a normolipemic skin-limited
disorder, although pediatric exceptions with abnormal lipid profiles have
been reported.
category: Rare Dermatologic Disorder
disease_term:
preferred_term: Papular xanthoma
term:
id: MONDO:0015536
label: papular xanthoma
parents:
- Non-Langerhans cell histiocytosis
- Cutaneous histiocytosis
synonyms:
- Papular xanthomatosis
pathophysiology:
- name: Xanthomatized Dermal Macrophage Infiltration
description: >
Papular xanthoma lesions represent a monomorphous non-Langerhans cell
histiocytosis reaction pattern dominated by xanthomatized macrophages in
skin. Foamy macrophage accumulation and Touton giant cells produce the
yellow papular clinical morphology and anchor the diagnosis histologically.
cell_types:
- preferred_term: xanthomatized macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: macrophage derived foam cell differentiation
term:
id: GO:0010742
label: macrophage derived foam cell differentiation
- preferred_term: lipid metabolic process
term:
id: GO:0006629
label: lipid metabolic process
downstream:
- target: Solitary or multiple papules
description: >
Dermal xanthomatized macrophage accumulation produces the papular lesion
morphology described clinically.
causal_link_type: DIRECT
- target: Foamy Xanthomatized Macrophage Infiltrate
description: >
The pathophysiologic macrophage accumulation is directly observed as the
foamy or xanthomatized dermal infiltrate on biopsy.
causal_link_type: DIRECT
- target: Touton Giant Cells
description: >
Xanthomatous macrophage-rich lesions are histologically accompanied by
Touton-type giant cells in the clinicopathologic series.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "presence of predominantly xanthomatized macrophages."
explanation: >
The 10-case clinicopathologic series defines papular xanthoma as a
non-Langerhans cell histiocytosis pattern dominated by xanthomatized
macrophages.
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "acanthoma. Histology showed moderately well circumscribed exoendophytic papules"
explanation: >
This directly links the clinical papule to dense xanthomatized macrophage
infiltration and Touton giant cells.
phenotypes:
- category: Dermatologic
name: Solitary or multiple papules
description: >
Papular xanthoma presents as cutaneous papules, usually solitary in the
adult clinicopathologic series but capable of multiple pediatric facial or
disseminated presentations.
phenotype_term:
preferred_term: Papule
term:
id: HP:0200034
label: Papule
evidence:
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "mainly as solitary papule, with a male to female ratio of4 : 1, in an age range"
explanation: >
The series supports papules as the core clinical morphology and documents
adolescent-to-adult presentations without using this as a frequency field.
- reference: PMID:20199419
reference_title: "Case report--papular xanthoma in a 10-year-old female with abnormal lipid profile."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "report a 10-year-old girl with multiple papule xanthomas on her face that had an"
explanation: >
This pediatric case supports that papular xanthoma can present with
multiple facial papules and that normolipemia is not absolute.
- category: Dermatologic
name: Yellow xanthomatous eyelid or periocular lesions
description: >
Xanthomatous lesions can involve eyelid or periocular skin and must be
distinguished from xanthelasma and other histiocytoses.
phenotype_term:
preferred_term: Yellow papule
term:
id: HP:0025507
label: Yellow papule
evidence:
- reference: PMID:21396554
reference_title: "Periorbital lesions."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Histiocytosis is rare but does occur in prevalent locations."
explanation: >
This periorbital-lesion review supports that histiocytoses can occur
around the eyes, but the abstract is not specific to papular xanthoma.
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "It was predominantly located on the trunk, the extremities, and rarely on the head."
explanation: >
This supports head involvement as a rare site in the clinicopathologic
series, but only partially supports a periocular/head-involvement claim
because the series emphasized trunk and extremity involvement.
histopathology:
- name: Foamy Xanthomatized Macrophage Infiltrate
description: >
Biopsy shows a circumscribed dermal papule with dense foamy or
xanthomatized macrophages.
finding_term:
preferred_term: foamy macrophage
term:
id: HP:0025461
label: Abnormal cell morphology
diagnostic: true
evidence:
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "with a regular epidermis and a dense infiltration of xanthomatized macrophages"
explanation: >
This exact histologic description supports foamy/xanthomatized macrophage
infiltrates as a diagnostic microscopic feature.
- name: Touton Giant Cells
description: >
Touton-type giant cells are commonly described in classic papular xanthoma
histology and help place the lesion among xanthomatous histiocytoses. A
precise HPO term for Touton giant cells was not found locally with OAK, and
no finding_term is assigned; an HPO new term request may be needed.
diagnostic: true
evidence:
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "interspersed by numerous Touton type giant cells. Immunohistochemically mono-"
explanation: >
The series explicitly identifies numerous Touton-type giant cells in
papular xanthoma histology.
diagnosis:
- name: Skin biopsy with histology and immunohistochemistry
description: >
Diagnosis is established by biopsy demonstrating xanthomatized macrophages
and Touton giant cells, with immunohistochemistry supporting a
non-Langerhans macrophage lineage.
diagnosis_term:
preferred_term: biopsy of skin
term:
id: MAXO:0000423
label: biopsy of skin
evidence:
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "OBJECTIVE: The purpose of this study was to identify the clinical, histological"
explanation: >
The foundational series used clinicopathologic, histologic, and
immunohistochemical characterization to define papular xanthoma.
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "and multinucleated macrophages were consistently positive with KiM1p; while only"
explanation: >
This supports immunohistochemistry as part of diagnostic confirmation and
documents macrophage marker reactivity.
- name: Immunohistochemical macrophage marker profile
description: >
Papular xanthoma immunohistochemistry supports non-Langerhans macrophage
lineage: mono- and multinucleated macrophages are KiM1p-positive, Touton
giant cells are KP1/CD68-positive, and factor XIIIa and CD1a are negative.
diagnosis_term:
preferred_term: immunohistochemistry
term:
id: NCIT:C23020
label: Immunohistochemistry Staining Method
markers: "KiM1p positive; KP1/CD68 positive in giant cells; factor XIIIa negative; CD1a negative"
evidence:
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "and multinucleated macrophages were consistently positive with KiM1p; while only"
explanation: >
This documents KiM1p positivity in mono- and multinucleated macrophages.
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "giant cells were labeled with KP1 (CD68), the reactivity with HAM 56 was much"
explanation: >
This documents KP1/CD68 labeling in Touton-type giant cells.
- reference: PMID:12028152
reference_title: "Papular xanthoma: a clinicopathological study of 10 cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Staining for factor XIIIa and CD1a were negative."
explanation: >
This documents the negative factor XIIIa and CD1a components of the
diagnostic immunohistochemical profile.
- name: Lipid and systemic evaluation
description: >
Papular xanthoma is classically normolipemic, but lipid testing is still
clinically relevant because abnormal pediatric lipid profiles have been
reported and eyelid xanthomatous lesions may overlap with systemic
disorders.
evidence:
- reference: PMID:20199419
reference_title: "Case report--papular xanthoma in a 10-year-old female with abnormal lipid profile."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Papular xanthoma is a rare normolipemic xanthomatous skin disease which"
explanation: >
This supports normolipemia as the classic framing of papular xanthoma.
- reference: PMID:20199419
reference_title: "Case report--papular xanthoma in a 10-year-old female with abnormal lipid profile."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "children, all but one reported in the literature had a normal lipid profile. We"
explanation: >
This supports lipid-profile evaluation and shows that normal lipids are
usual but not universal in reported pediatric disease.
differential_diagnoses:
- name: Juvenile xanthogranuloma
description: >
Juvenile xanthogranuloma is the key clinical and histopathologic mimic,
especially in infants and children with multiple yellow papules.
distinguishing_features:
- Papular xanthoma is modeled as a more monomorphous xanthomatized macrophage pattern.
- Immunohistochemistry and clinicopathologic correlation are needed for separation.
- name: Xanthelasma palpebrarum
description: >
Eyelid xanthomatous lesions may resemble xanthelasma palpebrarum, but
papular xanthoma belongs to the non-Langerhans cell histiocytosis group and
requires biopsy-based distinction when eyelid lesions are atypical.
distinguishing_features:
- Xanthelasma palpebrarum is the prototype localized eyelid xanthomatous lesion.
- Papular xanthoma is listed among normolipemic non-Langerhans cell histiocytoses that can cause xanthomatous eyelid lesions.
evidence:
- reference: PMID:28500693
reference_title: "The clinical spectrum of xanthomatous lesions of the eyelids."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "\"xanthelasma palpebrarum\" (XP) that is localized only to the eyelids and may be"
explanation: >
This supports xanthelasma palpebrarum as the main eyelid xanthomatous
comparator.
- reference: PMID:28500693
reference_title: "The clinical spectrum of xanthomatous lesions of the eyelids."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "cell histiocytoses (papular xanthoma, juvenile xanthogranuloma, xanthoma"
explanation: >
This explicitly places papular xanthoma among eyelid xanthomatous
non-Langerhans histiocytosis differentials.
treatments:
- name: Observation and supportive follow-up
description: >
No disease-specific standard pharmacotherapy is established in the fetched
abstracts. Management is therefore represented conservatively as supportive
follow-up after diagnosis, lipid evaluation, and assessment for systemic or
associated disorders when clinically indicated.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:28500693
reference_title: "The clinical spectrum of xanthomatous lesions of the eyelids."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "obtain a thorough history and exclude XP and then perform detailed"
explanation: >
This supports careful diagnostic evaluation and follow-up for
xanthomatous eyelid lesions, but it is not a papular-xanthoma-specific
treatment trial.
notes: >-
Falcon deep research identified additional case reports and treatment comments,
but several cited DOI caches had no fetchable abstract content. Claims here are
limited to snippets available from fetched PMID/DOI caches.
Papular xanthoma is very rare and much of the literature consists of case reports/series. The most directly informative recent source retrieved here is a 2023 case report with literature review (Journal of Cutaneous Pathology, May 2023). Several key clinicopathologic facts come from a foundational 10‑case series (2002) and pediatric case reports (2010–2020). (francois2023multiplepapularxanthomas pages 2-2, breier2002papularxanthomaa pages 1-2, ramessur2020eruptivepapulesin pages 1-2)
PMID note: PMIDs were not present in the retrieved text extracts; therefore this report cites DOI/URLs and the tool-provided context IDs.
Papular xanthoma (PX) is a rare, primarily cutaneous, xanthomatous lesion characterized by a dermal proliferation/infiltrate of lipid-laden (“foamy”) histiocytes/macrophages, typically occurring with normal serum lipid profiles (normolipemic) and classified among cutaneous non‑Langerhans cell histiocytoses. (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, breier2002papularxanthomaa pages 1-2)
The current understanding is derived predominantly from aggregated disease-level literature (case series and reviews) plus individual patient case reports, rather than EHR-scale evidence. (breier2002papularxanthomaa pages 2-4, francois2023multiplepapularxanthomas pages 2-2, ramessur2020eruptivepapulesin pages 1-2)
No single genetic cause or infectious agent was identified in the retrieved literature excerpts. PX is framed as a clinicopathologic entity within non‑Langerhans cell histiocytoses, defined by a macrophage/foam-cell infiltrate pattern rather than a known monogenic defect. (breier2002papularxanthomaa pages 2-4, breier2002papularxanthomaa pages 1-2)
No protective genetic or environmental factors were identified in the retrieved sources.
No gene–environment interaction evidence was identified in the retrieved sources.
Core phenotype: Asymptomatic yellow/yellow‑brown papules (sometimes papulonodules), often widespread; may be solitary or disseminated. (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2)
Distribution: - Adult series: trunk and extremities predominated; head less common; most were solitary lesions (9/10). (breier2002papularxanthomaa pages 1-2) - Pediatric PX: often head, trunk, extremities with sparing of mucosa, palms, soles, and generally flexures (except axillae), though presentations vary. (ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2)
Periorbital/eyelid involvement: PX can present with yellowish papulonodular lesions “often located around the eyes” in periorbital lesion reviews; eyelid involvement is illustrated in an eyelid-focused review of xanthomatous lesions. (rebora2011periorbitallesions. pages 4-5, baykal2017theclinicalspectrum pages 1-2)
Formal QoL instruments (e.g., DLQI, PROMIS) were not reported in the retrieved sources. The main impacts described are cosmetic burden and potential residual atrophic/hyperpigmented scarring after lesion regression in children. (ramessur2020eruptivepapulesin pages 1-2)
(These are suggested mappings based on described clinical findings; ontology IDs should be verified during curation.) - Yellow papules / xanthomatous papules → Xanthoma; Skin papule (ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2) - Periorbital distribution → Periorbital skin lesion (rebora2011periorbitallesions. pages 4-5) - Post-inflammatory hyperpigmentation / residual hyperpigmented macules → Hyperpigmentation of the skin (ramessur2020eruptivepapulesin pages 1-2) - Atrophic/anethoderma-like scarring → Atrophic scar / Anetoderma (ramessur2020eruptivepapulesin pages 1-2)
No causal genes or recurrent pathogenic variants were identified in the retrieved PX evidence.
PX lesions show a macrophage/histiocyte immunophenotype: - CD68 positive histiocytes are typical. (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2) - S100 negative and CD1a negative are repeatedly reported, supporting non‑Langerhans lineage. (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2) - Factor XIIIa (FXIIIa): variable across reports—positive in at least one pediatric case report and negative in the 10-case adult series and in an infant case review; this variability is important for differential diagnosis with juvenile xanthogranuloma and related entities. (ramessur2020eruptivepapulesin pages 1-2, breier2002papularxanthomaa pages 1-2, francois2023multiplepapularxanthomas pages 2-2)
(Conceptual mapping consistent with lesion composition; requires ontology verification.) - CL: macrophage / histiocyte (dominant foamy cells) (breier2002papularxanthomaa pages 2-4, breier2002papularxanthomaa pages 1-2) - GO Biological Process: lipid metabolic process / foam cell differentiation (inferred from “xanthomatized/foamy” macrophages; mechanistic detail not experimentally established for PX in these sources) (breier2002papularxanthomaa pages 2-4)
No specific toxins, occupational exposures, lifestyle factors, or infectious triggers were established as causal. Some case-based associations have been reported with inflammatory/eruptive contexts (viral/drug eruptions) but without mechanistic proof. (ramessur2020eruptivepapulesin pages 1-2)
PX is best understood as a localized cutaneous accumulation/proliferation of lipid-laden macrophages in the dermis, producing yellow papules/nodules. Histologically it is typically well delimited with dense infiltrates of xanthomatized cells and variable Touton giant cells, and with relative absence of inflammatory cells and lack of an early “primitive histiocytic” phase in classic descriptions. (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2)
PX is repeatedly emphasized as a key histopathologic/clinical mimic of JXG; some authors consider PX within a spectrum/variant of xanthogranuloma (xanthomatous pattern). (francois2023multiplepapularxanthomas pages 2-2, ramessur2020eruptivepapulesin pages 1-2)
No pathway-level (e.g., MAPK, PI3K-AKT) or omics profiling findings (transcriptomics/proteomics) were identified in the retrieved PX sources.
Not directly studied in retrieved sources; lipid-laden/foamy cytoplasm implies lipid droplets/lysosomal compartments, but this remains inferential here.
No population prevalence/incidence estimates were found in retrieved sources.
Case-count statistics from reviews/series: - 2002 clinicopathologic series noted: “Until now, 43 cases of cutaneous PX have been described” (at that time). (breier2002papularxanthomaa pages 2-4) - 2023 literature review summary cited ~53–54 patients reported across ~22 reports, and that 18 had follow-up (median 28 months; mean 41.3 months) with 2 recurrent/persistent lesions. (francois2023multiplepapularxanthomas pages 2-2, francois2023multiplepapularxanthomas pages 2-3)
No inheritance pattern is established in the retrieved literature. A family history of hypercholesterolemia was noted in one pediatric PX case, but causality/inheritance specific to PX was not established. (ramessur2020eruptivepapulesin pages 1-2)
Winkelmann’s PX diagnostic criteria (as reproduced in a pediatric diagnostic case discussion) include: 1) generalized asymptomatic yellowish papulonodular lesions without coalescing plaques, 2) normal lipid profile, 3) no visceral involvement, 4) foamy-cell predominant infiltrate, 5) absence of primitive histiocytic phase and inflammatory cells. (ramessur2020eruptivepapulesin pages 1-2)
Typical biopsy features include a well-delimited dermal tumor/infiltrate with a small grenz zone and dense infiltrate of foamy/xanthomatized histiocytes with numerous Touton-type giant cells (though Touton cells may be absent in some pediatric lesions). (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2)
Common IHC profile: - CD68+ histiocytes (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2) - S100−, CD1a− (helps exclude Langerhans cell histiocytosis) (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2) - FXIIIa: may be positive or negative depending on case/series; therefore should not be used as a sole discriminator. (ramessur2020eruptivepapulesin pages 1-2, breier2002papularxanthomaa pages 1-2, francois2023multiplepapularxanthomas pages 2-2)
From case reports and eyelid review guidance, commonly implemented evaluation includes: - Fasting lipid profile (including repeat testing if abnormal) (arbuckle2010casereport—papularxanthoma pages 1-3, ramessur2020eruptivepapulesin pages 1-2) - Screening for systemic disease/visceral involvement (e.g., ultrasound imaging in pediatric cases; chest X-ray in one report) (ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2) - Additional labs sometimes used: serum protein electrophoresis (SPEP) (arbuckle2010casereport—papularxanthoma pages 1-3) - Biopsy with histopathologic confirmation and IHC (ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2) - For xanthomatous eyelid lesions broadly: obtain history, exclude xanthelasma palpebrarum, detailed derm/systemic exam, biopsy, and “appropriate specific imaging screens.” (baykal2017theclinicalspectrum pages 1-2)
(Require MAXO ID verification during curation.) - Watchful waiting / observation (pediatric) (choudhary2015papularxanthomain pages 1-2) - Skin biopsy (diagnostic procedure; also a medical action) (ramessur2020eruptivepapulesin pages 1-2) - Systemic antibiotic therapy (doxycycline) — only case-level mention (choudhary2015papularxanthomain pages 1-2)
No primary prevention strategies are established. Practical prevention is limited to addressing modifiable lipid abnormalities if present and monitoring for associated conditions when clinically indicated. (arbuckle2010casereport—papularxanthoma pages 1-3, ramessur2020eruptivepapulesin pages 1-2)
No naturally occurring PX analog in non-human species was identified in the retrieved sources.
No PX-specific model organisms or induced experimental models were identified in the retrieved sources.
The 2023 case report with literature review consolidates modern understanding that PX can mimic JXG clinically and histologically, provides updated case counts (~53–54 total patients), and emphasizes age-dependent natural history (self-limited in many pediatric cases vs persistence/recurrence and systemic associations more often discussed in adults). (francois2023multiplepapularxanthomas pages 2-2, francois2023multiplepapularxanthomas pages 2-3)
Eyelid-focused review literature emphasizes that xanthomatous periocular lesions can reflect a spectrum of disorders, some with systemic/malignancy associations, and recommends thorough history, systemic examination, biopsy confirmation, and appropriate imaging when evaluating these presentations. (baykal2017theclinicalspectrum pages 1-2)
The following evidence-map table consolidates the most actionable facts for knowledge base population.
| Clinical domain | Key facts | Quantitative details | Evidence |
|---|---|---|---|
| Definition / classification | Papular xanthoma (PX) is a rare normolipemic cutaneous non-Langerhans cell histiocytosis and a monomorphous xanthomatized macrophage-predominant reaction pattern within the n-LCH spectrum. It was originally defined by Winkelmann as a distinct xanthogranulomatous/xanthomatous entity. | Largest older clinicopathologic series: 10 cases. | (breier2002papularxanthomaa pages 1-2, breier2002papularxanthomaa pages 2-4) |
| Lipid profile status | PX is classically described as normolipemic, and diagnostic criteria include a normal lipid profile and no visceral involvement. However, exceptions have been reported, including pediatric cases with lipid abnormalities and historical association with dysbetalipoproteinemia, suggesting the criterion is not absolute. | In one pediatric case, triglycerides were 334 mg/dL initially and 241 mg/dL on repeat fasting test; cholesterol 134 mg/dL then 145 mg/dL. | (ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2, arbuckle2010casereport—papularxanthoma pages 1-3) |
| Age of onset patterns | PX occurs in both children and adults. Adult series showed a biphasic occurrence in adolescence and middle age. Pediatric disease usually starts in the first year of life, but later childhood onset also occurs. | Adult series age range 13-57 years; pediatric onset in ~90% during the first year of life; one case began at age 3 years, another at 4.5 years, another at 10 years. | (breier2002papularxanthomaa pages 1-2, ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2, arbuckle2010casereport—papularxanthoma pages 1-3) |
| Distribution / anatomic sites | Lesions are typically yellow to yellow-brown papules/nodules, often on trunk and extremities; head/neck involvement can occur. Pediatric cases often involve head, trunk, and extremities with sparing of mucosa, palms, soles, and usually flexures. Eyelid/periorbital involvement is documented and may appear as flat plaques or papulonodular xanthomatous lesions. | In the 10-case series, trunk was most common (50%); 9/10 were solitary and 1/10 disseminated. | (breier2002papularxanthomaa pages 1-2, ramessur2020eruptivepapulesin pages 1-2, francois2023multiplepapularxanthomas pages 2-2, choudhary2015papularxanthomain pages 1-2, baykal2017theclinicalspectrum pages 4-6, baykal2017theclinicalspectrum pages 1-2, rebora2011periorbitallesions. pages 4-5) |
| Histopathology | PX shows a well-delimited dermal infiltrate of foamy/xanthomatized histiocytes/macrophages, often with Touton giant cells, a relative absence of inflammatory cells, and no primitive histiocytic phase. Pediatric lesions may lack giant cells and remain monomorphic. | Some childhood cases show no multinucleated/Touton giant cells; others show moderate/numerous Touton cells. | (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, francois2023multiplepapularxanthomas pages 2-2, francois2023multiplepapularxanthomas pages 2-3, ramessur2020eruptivepapulesin pages 2-2, breier2002papularxanthomaa pages 1-2, choudhary2015papularxanthomain pages 1-2) |
| Immunohistochemistry | PX usually shows CD68 positivity and is typically S100-negative and CD1a-negative. Factor XIIIa findings are variable across reports: negative in the 10-case adult series and some recent infant data, but positive in at least one pediatric case. In the 2002 series, KiM1p was consistently positive; KP1/CD68 labeled mainly giant cells; HAM56 was variable. | Marker pattern summary: CD68+, S100-, CD1a-; FXIIIa variable; KiM1p+ in the adult series. | (breier2002papularxanthomaa pages 1-2, breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, francois2023multiplepapularxanthomas pages 2-2, francois2023multiplepapularxanthomas pages 2-3, choudhary2015papularxanthomain pages 1-2) |
| Key differential diagnoses | Important differentials include juvenile xanthogranuloma (JXG), xanthoma disseminatum (XD), benign cephalic histiocytosis (BCH), Spitz nevus, clear cell acanthoma, xanthoma, atheroma, keloid, histiocytoma, and in some facial cases granulomatous/perioral dermatitis. Distinguishing features rely on biopsy and immunophenotype. | JXG is the principal histopathologic mimic; PX differs by monomorphic foamy-cell infiltrate and relative lack of inflammatory cells/primitive phase. | (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, francois2023multiplepapularxanthomas pages 2-2, choudhary2015papularxanthomain pages 1-2, breier2002papularxanthomaa pages 1-2, arbuckle2010casereport—papularxanthoma pages 1-3) |
| Reported associations | PX is usually isolated, but reported associations include mycosis fungoides, Sezary syndrome, later CD3(dim)/CD4+ T-cell lymphoma, dysbetalipoproteinemia, erythrodermic chronic actinic dermatitis, and viral/drug eruptions. Systemic associations remain uncertain overall. | Eyelid review documented at least one patient with PX plus mycosis fungoides. | (ramessur2020eruptivepapulesin pages 1-2, choudhary2015papularxanthomain pages 1-2, ramessur2020eruptivepapulesin pages 2-2, baykal2017theclinicalspectrum pages 4-6, baykal2017theclinicalspectrum pages 1-2) |
| Natural history / prognosis | Childhood PX is generally self-limited, with lesion flattening and residual hyperpigmentation or anetoderma-like change; adults may show persistent, progressive, or recurrent disease. Observation is typical in children. | Childhood lesions often regress within 1-5 years; most regress within 5 years; anetoderma-like scarring reported in up to 60%; one child had improvement over 3 years with no new lesions. | (breier2002papularxanthomaa pages 2-4, ramessur2020eruptivepapulesin pages 1-2, francois2023multiplepapularxanthomas pages 2-2, choudhary2015papularxanthomain pages 1-2, ramessur2020eruptivepapulesin pages 2-2) |
| Epidemiology / case counts | PX is very rare, with literature estimates differing by review date and inclusion criteria. Older and newer reviews consistently indicate only a few dozen documented patients. | Older review: 43 cutaneous cases before the 2002 series; 2023 review states 53 reported patients with 35 in four comprehensive series and 18 with follow-up (median 28 months, mean 41.3 months); another 2023 summary states 22 reports / 54 patients. | (breier2002papularxanthomaa pages 2-4, francois2023multiplepapularxanthomas pages 2-2, francois2023multiplepapularxanthomas pages 2-3, breier2002papularxanthomaa pages 1-2) |
| Suggested workup from reported practice | Reported evaluation includes fasting lipid profile, CBC/basic labs, serum protein electrophoresis, assessment for visceral/systemic involvement, skin biopsy with histology and immunohistochemistry, and when periocular disease is present, broader dermatologic/systemic assessment. | Pediatric workups included normal abdominal ultrasound/chest X-ray in one case and normal liver/spleen ultrasound in another. | (ramessur2020eruptivepapulesin pages 1-2, arbuckle2010casereport—papularxanthoma pages 1-3, choudhary2015papularxanthomain pages 1-2, baykal2017theclinicalspectrum pages 1-2) |
Table: This table compiles the main clinically actionable facts about papular xanthoma from the provided evidence, including phenotype, pathology, immunohistochemistry, associations, prognosis, and reported case statistics. It is useful as a compact evidence map for building a disease knowledge base entry.
References
(francois2023multiplepapularxanthomas pages 2-2): Rony A. Francois, Grant J. Randall, Eric W. Rudnick, Stephanie J. Carstens, and Vladimir Vincek. Multiple papular xanthomas mimicking juvenile xanthogranulomas in an infant: a case report and review of the literature. Journal of Cutaneous Pathology, 50:1-7, May 2023. URL: https://doi.org/10.1111/cup.14244, doi:10.1111/cup.14244. This article has 0 citations and is from a peer-reviewed journal.
(breier2002papularxanthomaa pages 1-2): Friedrich Breier, Bettina Zelger, Harald Reiter, Friedrich Gschnait, and Bernhard W. H. Zelger. Papular xanthoma: a clinicopathological study of 10 cases. Journal of Cutaneous Pathology, 29:200-206, Apr 2002. URL: https://doi.org/10.1034/j.1600-0560.2002.290402.x, doi:10.1034/j.1600-0560.2002.290402.x. This article has 52 citations and is from a peer-reviewed journal.
(ramessur2020eruptivepapulesin pages 1-2): Ravi Ramessur, George Meligonis, and Nigel P. Burrows. Eruptive papules in a 4‐year‐old girl. Pediatric Dermatology, Jan 2020. URL: https://doi.org/10.1111/pde.14023, doi:10.1111/pde.14023. This article has 0 citations and is from a peer-reviewed journal.
(breier2002papularxanthomaa pages 2-4): Friedrich Breier, Bettina Zelger, Harald Reiter, Friedrich Gschnait, and Bernhard W. H. Zelger. Papular xanthoma: a clinicopathological study of 10 cases. Journal of Cutaneous Pathology, 29:200-206, Apr 2002. URL: https://doi.org/10.1034/j.1600-0560.2002.290402.x, doi:10.1034/j.1600-0560.2002.290402.x. This article has 52 citations and is from a peer-reviewed journal.
(baykal2017theclinicalspectrum pages 1-2): Can Baykal, Algun Polat Ekinci, Kurtulus D. Yazganoglu, and Nesimi Buyukbabani. The clinical spectrum of xanthomatous lesions of the eyelids. International Journal of Dermatology, 56:981-992, May 2017. URL: https://doi.org/10.1111/ijd.13637, doi:10.1111/ijd.13637. This article has 38 citations and is from a peer-reviewed journal.
(arbuckle2010casereport—papularxanthoma pages 1-3): Alan Arbuckle and Lori D. Prok. Case report—papular xanthoma in a 10‐year‐old female with abnormal lipid profile. Pediatric Dermatology, 27:86-88, Jan 2010. URL: https://doi.org/10.1111/j.1525-1470.2009.01054.x, doi:10.1111/j.1525-1470.2009.01054.x. This article has 9 citations and is from a peer-reviewed journal.
(choudhary2015papularxanthomain pages 1-2): Nidhi Choudhary, Shruti Jadhav, Rahul Ahar, Arghyaprasun Ghosh, Joydeep Singha, and Archana Saha. Papular xanthoma in a child: report of a rare entity. Indian Journal of Paediatric Dermatology, 16:78-80, Apr 2015. URL: https://doi.org/10.4103/2319-7250.152139, doi:10.4103/2319-7250.152139. This article has 2 citations.
(rebora2011periorbitallesions. pages 4-5): Alfredo Rebora. Periorbital lesions. Clinics in dermatology, 29 2:151-6, Mar 2011. URL: https://doi.org/10.1016/j.clindermatol.2010.09.006, doi:10.1016/j.clindermatol.2010.09.006. This article has 9 citations and is from a peer-reviewed journal.
(francois2023multiplepapularxanthomas pages 2-3): Rony A. Francois, Grant J. Randall, Eric W. Rudnick, Stephanie J. Carstens, and Vladimir Vincek. Multiple papular xanthomas mimicking juvenile xanthogranulomas in an infant: a case report and review of the literature. Journal of Cutaneous Pathology, 50:1-7, May 2023. URL: https://doi.org/10.1111/cup.14244, doi:10.1111/cup.14244. This article has 0 citations and is from a peer-reviewed journal.
(baykal2017theclinicalspectrum pages 4-6): Can Baykal, Algun Polat Ekinci, Kurtulus D. Yazganoglu, and Nesimi Buyukbabani. The clinical spectrum of xanthomatous lesions of the eyelids. International Journal of Dermatology, 56:981-992, May 2017. URL: https://doi.org/10.1111/ijd.13637, doi:10.1111/ijd.13637. This article has 38 citations and is from a peer-reviewed journal.
(ramessur2020eruptivepapulesin pages 2-2): Ravi Ramessur, George Meligonis, and Nigel P. Burrows. Eruptive papules in a 4‐year‐old girl. Pediatric Dermatology, Jan 2020. URL: https://doi.org/10.1111/pde.14023, doi:10.1111/pde.14023. This article has 0 citations and is from a peer-reviewed journal.